


COMPASS

Trial design: Patients with stable atherosclerosis were randomized to rivaroxaban 2.5 mg twice daily plus aspirin (n = 9,152) vs. rivaroxaban alone (n = 9,117) vs. aspirin alone (n = 9,126).

(p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone)



 Rivaroxaban plus aspirin

 Rivaroxaban alone

 Aspirin alone

www.acc.org

Results

- Cardiovascular death, MI, or stroke: 4.1% of the rivaroxaban plus aspirin group vs. 4.9% of the rivaroxaban alone group vs. 5.4% of the aspirin alone group (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone)

Conclusions

- Among patients with stable atherosclerosis, rivaroxaban plus aspirin was associated with fewer adverse cardiovascular events compared with aspirin alone

Eikelboom JW, et al. N Engl J Med 2017;Aug 27:[Epub]